NCT05161195 2026-02-02Roll-over Study to Allow Continued Access to RibociclibNovartisPhase 4 Active not recruiting134 enrolled
NCT02447328 2021-09-05A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast CancerAstraZenecaPhase 4 Completed83 enrolled 6 charts
NCT04031885 2021-08-24A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast CancerEli Lilly and CompanyPhase 4 Terminated4 enrolled 9 charts